Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Identifying DNA Methylation Mediators of Field Defect in Colorectal Cancer using Whole Methylome Analysis
FY 2014-15
Summary
Colorectal cancer (CRC) initiation and progression are associated with the accumulation of genetic and epigenetic alterations. Epigenetic mechanisms are processes that can alter gene expression without changing the primary sequence of DNA. The best-characterized epigenetic process is DNA methylation, which regulates gene expression by addition of a methyl group to specific sites on DNA. Aberrant DNA methylation can lead to cancer by altering the expression of cancer-related genes and inducing DNA instability.
Changes in DNA methylation can also mediate field defect, a phenomenon in which normal-appearing tissues are predisposed to cancer due to the presence of molecular aberrations. In this study, we obtained paired tumour tissue with adjacent and distant normal colorectal tissues from 90 CRC patients. The goal of my project is to identify DNA methylation mediators of field defect in CRC by comparing DNA methylation profiles of tumour, adjacent, and distant normal tissues. We hypothesize that specific aberrant DNA methylation patterns in tumours will be detected in adjacent normal (but not distant normal) tissues which may represent early molecular alterations driving cancer development.
Identification of aberrant DNA methylation mediating field defect will determine molecular alterations preceding formation of precursor lesions and CRC, which is a more effective strategy for disease surveillance than screening for tumour biomarkers. This study will not only provide insights on the biology of CRC, but it will also translate basic science research into a clinically applicable tool through the application of DNA methylation markers in early detection, risk assessment, disease monitoring, and therapeutic intervention of CRC.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331599
Name
Yap Eva Shyong Quin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying DNA Methylation Mediators of Field Defect in Colorectal Cancer using Whole Methylome Analysis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer Detection And Risk Assessment; Colorectal Cancer; Dna Methylation; Epigenomics; Field Defect
Abstract
Colorectal cancer (CRC) initiation and progression are associated with the accumulation of genetic and epigenetic alterations. Epigenetic mechanisms are processes that can alter gene expression without changing the primary sequence of DNA. The best-characterized epigenetic process is DNA methylation, which regulates gene expression by addition of a methyl group to specific sites on DNA. Aberrant DNA methylation can lead to cancer by altering the expression of cancer-related genes and inducing DNA instability.
Changes in DNA methylation can also mediate field defect, a phenomenon in which normal-appearing tissues are predisposed to cancer due to the presence of molecular aberrations. In this study, we obtained paired tumour tissue with adjacent and distant normal colorectal tissues from 90 CRC patients. The goal of my project is to identify DNA methylation mediators of field defect in CRC by comparing DNA methylation profiles of tumour, adjacent, and distant normal tissues. We hypothesize that specific aberrant DNA methylation patterns in tumours will be detected in adjacent normal (but not distant normal) tissues which may represent early molecular alterations driving cancer development.
Identification of aberrant DNA methylation mediating field defect will determine molecular alterations preceding formation of precursor lesions and CRC, which is a more effective strategy for disease surveillance than screening for tumour biomarkers. This study will not only provide insights on the biology of CRC, but it will also translate basic science research into a clinically applicable tool through the application of DNA methylation markers in early detection, risk assessment, disease monitoring, and therapeutic intervention of CRC.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yap, Eva Shyong Quin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~